| pubmed-article:9834820 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9834820 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:9834820 | lifeskim:mentions | umls-concept:C0214192 | lld:lifeskim |
| pubmed-article:9834820 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:9834820 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9834820 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:9834820 | pubmed:dateCreated | 1999-2-3 | lld:pubmed |
| pubmed-article:9834820 | pubmed:abstractText | 9-Aminocamptothecin (9-AC) is a synthetic analogue of camptothecin. Phase I studies, identified the maximum tolerated dose as 1416 micrograms/m2/day x 3 as continuous intravenous infusion (CVI) with dose-limiting neutropenia. | lld:pubmed |
| pubmed-article:9834820 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9834820 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9834820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9834820 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9834820 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9834820 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:GolombH MHM | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:KrauseEE | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:HoffmanP CPC | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:RatainM JMJ | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:VokesE EEE | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:BeeH LHL | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:KlepschAA | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:MastersG AGA | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:FishkinP APA | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:AnsariR HRH | lld:pubmed |
| pubmed-article:9834820 | pubmed:author | pubmed-author:SciortinoD... | lld:pubmed |
| pubmed-article:9834820 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9834820 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9834820 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9834820 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9834820 | pubmed:pagination | 1085-90 | lld:pubmed |
| pubmed-article:9834820 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:meshHeading | pubmed-meshheading:9834820-... | lld:pubmed |
| pubmed-article:9834820 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9834820 | pubmed:articleTitle | A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. | lld:pubmed |
| pubmed-article:9834820 | pubmed:affiliation | University of Chicago, Department of Medicine, USA. | lld:pubmed |
| pubmed-article:9834820 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9834820 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9834820 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9834820 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9834820 | lld:pubmed |
